This will be a randomized, double-blind, single-dose, three-period balanced crossover study
in adult healthy subjects. Each of the 18 subjects will be randomized to receive a treatment
sequence consisting of each of the three treatments (FF 400 microgram (mcg), UMEC 500 mcg and
FF 400 mcg/UMEC 500 mcg), in three consecutive periods, with a wash-out period of 7 to 10
days between the periods.
The study will include a Screening period (28 days prior to first dose), Treatment period (3
single dose periods separated by two 7 to 10 days washout periods) and Follow-up period (7 to
14 days post last dose).
The pharmacokinetic (PK) and safety assessments will be performed during the study at fixed